Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OptiNose Inc OPTN

Healthcare
OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and... see more

Recent & Breaking News (NDAQ:OPTN)

Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE

GlobeNewswire May 4, 2023

Optinose Announces Reporting Date for First Quarter 2023 Financial Results

GlobeNewswire May 1, 2023

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 18, 2023

Optinose to Present at the Needham Virtual Healthcare Conference

GlobeNewswire April 12, 2023

Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

GlobeNewswire March 7, 2023

Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results

GlobeNewswire February 28, 2023

Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion

GlobeNewswire February 21, 2023

Optinose Announces CEO Transition and Business Update

GlobeNewswire January 31, 2023

Optinose Appoints Paul Spence as Chief Commercial Officer

GlobeNewswire December 15, 2022

Optinose Announces Departure of Acting Chief Financial Officer

GlobeNewswire December 9, 2022

Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference

GlobeNewswire November 30, 2022

Optinose Announces Pricing of Public Offering of Common Stock and Warrants

GlobeNewswire November 21, 2022

Optinose Announces Proposed Public Offering of Common Stock and Warrants

GlobeNewswire November 21, 2022

Optinose Reports Third Quarter 2022 Financial Results and Operational Updates

GlobeNewswire November 10, 2022

Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting

GlobeNewswire November 9, 2022

Optinose Announces Reporting Date for Third Quarter 2022 Financial Results

GlobeNewswire November 7, 2022

Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022

GlobeNewswire October 21, 2022

Optinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting

GlobeNewswire September 6, 2022

Optinose Reports Second Quarter 2022 Financial Results and Operational Updates

GlobeNewswire August 11, 2022

Optinose Announces Reporting Date for Second Quarter 2022 Financial Results

GlobeNewswire August 8, 2022